BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

303 related articles for article (PubMed ID: 28950290)

  • 1. Meta-analysis of individual patient safety data from six randomized, placebo-controlled trials with the antiangiogenic VEGFR2-binding monoclonal antibody ramucirumab.
    Arnold D; Fuchs CS; Tabernero J; Ohtsu A; Zhu AX; Garon EB; Mackey JR; Paz-Ares L; Baron AD; Okusaka T; Yoshino T; Yoon HH; Das M; Ferry D; Zhang Y; Lin Y; Binder P; Sashegyi A; Chau I
    Ann Oncol; 2017 Dec; 28(12):2932-2942. PubMed ID: 28950290
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ramucirumab Safety in East Asian Patients: A Meta-Analysis of Six Global, Randomized, Double-Blind, Placebo-Controlled, Phase III Clinical Trials.
    Yen CJ; Muro K; Kim TW; Kudo M; Shih JY; Lee KW; Chao Y; Kim SW; Yamazaki K; Sohn J; Cheng R; Zhang Y; Binder P; Mi G; Orlando M; Chung HC
    J Glob Oncol; 2018 Jul; 4():1-12. PubMed ID: 30085888
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of angiogenesis biomarkers for ramucirumab efficacy in patients with metastatic colorectal cancer from RAISE, a global, randomized, double-blind, phase III study.
    Tabernero J; Hozak RR; Yoshino T; Cohn AL; Obermannova R; Bodoky G; Garcia-Carbonero R; Ciuleanu TE; Portnoy DC; Prausová J; Muro K; Siegel RW; Konrad RJ; Ouyang H; Melemed SA; Ferry D; Nasroulah F; Van Cutsem E
    Ann Oncol; 2018 Mar; 29(3):602-609. PubMed ID: 29228087
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk of bleeding associated with antiangiogenic monoclonal antibodies bevacizumab and ramucirumab: a meta-analysis of 85 randomized controlled trials.
    Xiao B; Wang W; Zhang D
    Onco Targets Ther; 2018; 11():5059-5074. PubMed ID: 30174444
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I study of every 2- or 3-week dosing of ramucirumab, a human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2 in patients with advanced solid tumors.
    Chiorean EG; Hurwitz HI; Cohen RB; Schwartz JD; Dalal RP; Fox FE; Gao L; Sweeney CJ
    Ann Oncol; 2015 Jun; 26(6):1230-1237. PubMed ID: 25787923
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of Early Adverse Events on Survival Outcomes of Patients with Metastatic Colorectal Cancer Treated with Ramucirumab.
    Lim HH; Hopkins AM; Rowland A; Yuen HY; Karapetis CS; Sorich MJ
    Target Oncol; 2019 Dec; 14(6):743-748. PubMed ID: 31676953
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biomarker analyses in REGARD gastric/GEJ carcinoma patients treated with VEGFR2-targeted antibody ramucirumab.
    Fuchs CS; Tabernero J; Tomášek J; Chau I; Melichar B; Safran H; Tehfe MA; Filip D; Topuzov E; Schlittler L; Udrea AA; Campbell W; Brincat S; Emig M; Melemed SA; Hozak RR; Ferry D; Caldwell CW; Ajani JA
    Br J Cancer; 2016 Oct; 115(8):974-982. PubMed ID: 27623234
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and Safety of Ramucirumab With Docetaxel Versus Placebo With Docetaxel as Second-Line Treatment of Advanced Non-Small-Cell Lung Cancer: A Subgroup Analysis According to Patient Age in the REVEL Trial.
    Ramalingam SS; Pérol M; Reck M; Kowalyszyn RD; Gautschi O; Kimmich M; Cho EK; Czyzewicz G; Grigorescu A; Karaseva N; Dakhil S; Lee P; Zimmerman A; Sashegyi A; Alexandris E; Carter GC; Winfree KB; Garon EB
    Clin Lung Cancer; 2018 May; 19(3):270-279.e3. PubMed ID: 29373274
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial.
    Fuchs CS; Tomasek J; Yong CJ; Dumitru F; Passalacqua R; Goswami C; Safran H; Dos Santos LV; Aprile G; Ferry DR; Melichar B; Tehfe M; Topuzov E; Zalcberg JR; Chau I; Campbell W; Sivanandan C; Pikiel J; Koshiji M; Hsu Y; Liepa AM; Gao L; Schwartz JD; Tabernero J;
    Lancet; 2014 Jan; 383(9911):31-39. PubMed ID: 24094768
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas (JVDF): a multicohort, non-randomised, open-label, phase 1a/b trial.
    Herbst RS; Arkenau HT; Santana-Davila R; Calvo E; Paz-Ares L; Cassier PA; Bendell J; Penel N; Krebs MG; Martin-Liberal J; Isambert N; Soriano A; Wermke M; Cultrera J; Gao L; Widau RC; Mi G; Jin J; Ferry D; Fuchs CS; Petrylak DP; Chau I
    Lancet Oncol; 2019 Aug; 20(8):1109-1123. PubMed ID: 31301962
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Age does not influence efficacy of ramucirumab in advanced gastric cancer: Subgroup analyses of REGARD and RAINBOW.
    Muro K; Cho JY; Bodoky G; Goswami C; Chao Y; Dos Santos LV; Shimada Y; Topuzov E; Van Cutsem E; Tabernero J; Zalcberg J; Chau I; Cascinu S; Cheng R; Hsu Y; Emig M; Orlando M; Fuchs C
    J Gastroenterol Hepatol; 2018 Apr; 33(4):814-824. PubMed ID: 28960444
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Incidence and risk of hypertension associated with ramucirumab in cancer patients: A systematic review and meta-analysis.
    Qi WX; Fu S; Zhang Q; Guo XM
    J Cancer Res Ther; 2016; 12(2):775-81. PubMed ID: 27461650
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of weekly paclitaxel with or without ramucirumab as second-line therapy for the treatment of advanced gastric or gastroesophageal junction adenocarcinoma (RAINBOW-Asia): a randomised, multicentre, double-blind, phase 3 trial.
    Xu RH; Zhang Y; Pan H; Feng J; Zhang T; Liu T; Qin Y; Qin S; Yin X; Liu B; Ba Y; Yang N; Voon PJ; Tanasanvimon S; Zhou C; Zhang WL; Shen L
    Lancet Gastroenterol Hepatol; 2021 Dec; 6(12):1015-1024. PubMed ID: 34626550
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized, Double-Blind Phase Ib/III Study of Erlotinib With Ramucirumab or Placebo in Previously Untreated EGFR-Mutant Metastatic Non-Small-Cell Lung Cancer (RELAY): Phase Ib Results.
    Reck M; Garon EB; Paz-Ares L; Ponce S; Jaime JC; Juan O; Nadal E; Kiura K; Widau RC; He S; Dalal R; Lee P; Nakagawa K
    Clin Lung Cancer; 2018 May; 19(3):213-220.e4. PubMed ID: 29317191
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial.
    Wilke H; Muro K; Van Cutsem E; Oh SC; Bodoky G; Shimada Y; Hironaka S; Sugimoto N; Lipatov O; Kim TY; Cunningham D; Rougier P; Komatsu Y; Ajani J; Emig M; Carlesi R; Ferry D; Chandrawansa K; Schwartz JD; Ohtsu A;
    Lancet Oncol; 2014 Oct; 15(11):1224-35. PubMed ID: 25240821
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2.
    Spratlin JL; Cohen RB; Eadens M; Gore L; Camidge DR; Diab S; Leong S; O'Bryant C; Chow LQ; Serkova NJ; Meropol NJ; Lewis NL; Chiorean EG; Fox F; Youssoufian H; Rowinsky EK; Eckhardt SG
    J Clin Oncol; 2010 Feb; 28(5):780-7. PubMed ID: 20048182
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised, placebo-controlled, phase 3 trial.
    Fuchs CS; Shitara K; Di Bartolomeo M; Lonardi S; Al-Batran SE; Van Cutsem E; Ilson DH; Alsina M; Chau I; Lacy J; Ducreux M; Mendez GA; Alavez AM; Takahari D; Mansoor W; Enzinger PC; Gorbounova V; Wainberg ZA; Hegewisch-Becker S; Ferry D; Lin J; Carlesi R; Das M; Shah MA;
    Lancet Oncol; 2019 Mar; 20(3):420-435. PubMed ID: 30718072
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ramucirumab: targeting angiogenesis in the treatment of gastric cancer.
    Smyth EC; Tarazona N; Chau I
    Immunotherapy; 2014; 6(11):1177-86. PubMed ID: 25496333
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk of high-grade bleeding in patients with cancer treated with bevacizumab: a meta-analysis of randomized controlled trials.
    Hang XF; Xu WS; Wang JX; Wang L; Xin HG; Zhang RQ; Ni W
    Eur J Clin Pharmacol; 2011 Jun; 67(6):613-23. PubMed ID: 21243343
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of First-line S-1 Plus Oxaliplatin With or Without Ramucirumab Followed by Paclitaxel Plus Ramucirumab on Advanced Gastric Cancer in East Asia: The Phase 2 RAINSTORM Randomized Clinical Trial.
    Yoshikawa T; Muro K; Shitara K; Oh DY; Kang YK; Chung HC; Kudo T; Chin K; Kadowaki S; Hamamoto Y; Hironaka S; Yoshida K; Yen CJ; Omuro Y; Bai LY; Maeda K; Ozeki A; Yoshikawa R; Kitagawa Y
    JAMA Netw Open; 2019 Aug; 2(8):e198243. PubMed ID: 31373648
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.